IngredientsTrypsin carries the IUBMB nomenclature designation EC 3.4.21.4, with synonyms including α-trypsin and β-trypsin. Its CAS registry number is 9002-07-7. Trypsin is a type of serine protease enzyme from the PA clan superfamily found in the digestive system of many vertebrates, where it initiates the digestion of proteins by hydrolysis, cutting long chains of amino acids into smaller pieces. It is classified as a serine endopeptidase characterized by its preferential cleavage of peptide bonds on the carboxyl side of the basic amino acid residues lysine and arginine, enabling it to hydrolyze proteins into smaller peptides and playing a key role in digestive processes.
Trypsin is a 23,800-dalton protease with six disulfide bridges. The molecular weight of trypsin sits at 23.3 kDa from bovine and porcine sources, and its ideal pH range is anywhere between 7.5 and 8.5. This alkaline pH optimum distinguishes trypsin from the gastric protease pepsin, which functions under acidic conditions.
Trypsin is produced by the pancreas in an inactive form called trypsinogen. The trypsinogen enters the small intestine through the common bile duct and is converted to active trypsin. Occurring naturally in the small intestines of vertebrates, trypsin breaks down proteins as a component of the digestive process. Initially, it exists in the pancreas as trypsinogen before conversion to the active trypsin state by the enzyme enteropeptidase via proteolytic cleavage. Trypsin then interacts with pepsin and chymotrypsin to separate proteins into peptides and amino acids.
For use as a supplement, trypsin and chymotrypsin are extracted from the pancreas of various animals, primarily pigs and cows. The food enzyme is produced from the pancreas of pigs (Sus scrofa domesticus). It is exclusively obtained from the pancreas of animals slaughtered and approved for human consumption, free of notifiable diseases such as African swine fever, classical swine fever, foot-and-mouth disease, and swine vesicular disease.
Trypsin can be broadly divided into two types: recombinant trypsin and non-recombinant trypsin. Non-recombinant trypsin is derived from animal extraction, with animal origin, and represents the traditional use of trypsin, commonly found in the animal digestive system and directly extracted from the pancreatic tissue of cattle or pigs. Recombinant trypsin is produced using genetic recombinant technology and is not of animal origin. In the production process of modern biopharmaceuticals, the use of raw materials containing animal origin may bring potential virus sources that cause zoonotic diseases such as BSE (mad cow disease) and foot-and-mouth disease virus into the product; recombinant trypsin was developed through genetic engineering technology to solve the risk of virus contamination that may be brought by traditional porcine or bovine trypsin.
In 1876, Wilhelm Kühne discovered the protein-digesting enzyme trypsin. Trypsin was first identified in 1876 by the German physiologist Wilhelm Kühne, who isolated the enzyme from pancreatic extracts and named it "trypsin," derived from the Greek word tripsis meaning "rubbing," in reference to the method used to extract it by rubbing pancreatic tissue with glycerol. Kühne recognized trypsin as a proteolytic enzyme responsible for protein digestion in the pancreas, distinguishing it from other digestive enzymes like pepsin based on its activity in alkaline conditions and its specificity for peptide bonds. His work laid the foundation for understanding pancreatic secretion's role in metabolism, with initial studies focusing on its physiological function in breaking down dietary proteins into peptides.
Thanks to his skill in purifying and crystallizing digestive enzymes, Moses Kunitz established in the 1920s and 1930s not only that trypsin is synthesized and secreted by the pancreas as an inactive precursor enzyme, converted to active trypsin only when in contact with the intestinal brush-border enzyme enterokinase. The conclusion that pure proteins can be enzymes was definitively proved by Northrop and Stanley, who worked on the digestive enzymes pepsin (1930), trypsin, and chymotrypsin. These three scientists were awarded the 1946 Nobel Prize in Chemistry.
Proteolytic enzymes have been used to facilitate tissue repair since ancient times. Trypsin:chymotrypsin is an oral proteolytic enzyme preparation which has been in clinical use since the 1960s.
While trypsin itself was not a named substance in pre-modern pharmacopeias, the broader category of proteolytic enzyme activity was empirically exploited across many cultures. Papaya and pineapple are two of the richest plant sources of proteolytic enzymes, as attested by their traditional use as natural tenderizers for meat. Papain and bromelain are proteolytic enzymes found in these fruits. Trypsin, as an endogenous pancreatic enzyme, entered the arena of deliberate therapeutic preparation only after its scientific identification in the 19th century.
Proteolytic enzymes have been used to facilitate tissue repair since ancient times. Trypsin:chymotrypsin is an oral proteolytic enzyme preparation which has been in clinical use since the 1960s. Early pharmaceutical use involved oral and topical application for wound debridement, post-surgical swelling, and management of inflammatory conditions, particularly in European and South Asian medical traditions. The combination of trypsin with chymotrypsin became especially widespread in India, where it is still a prescription pharmaceutical.
Trypsin is a serine endopeptidase that catalyses the hydrolysis of peptide bonds on the carboxyl-terminal (C-terminal) side of the amino acids lysine and arginine, releasing polypeptides. This active trypsin acts with the other two principal digestive proteinases—pepsin and chymotrypsin—to break down dietary protein into peptides and amino acids. These amino acids are essential for muscle growth, hormone production, and other important bodily functions.
The enzyme is synthesized as the inactive precursor trypsinogen, which is subsequently activated to yield the mature form. Early investigations into trypsin's biochemistry revealed its production as an inactive precursor, trypsinogen, which is activated in the intestine. In the late 19th century, researchers noted that enterokinase, an enzyme from the duodenal mucosa, catalyzed this activation. This zymogen mechanism is a critical biological safeguard against autodigestion of the pancreas.
Although serine proteases are usually considered to act principally as degradative enzymes, certain proteases are signaling molecules that specifically regulate cells by cleaving and triggering members of a new family of proteinase-activated receptors (PARs). There are three members of this family: PAR-1 and PAR-3, which are receptors for thrombin, and PAR-2, a receptor for trypsin and mast cell tryptase. Proteases cleave within the extracellular NH2-terminus of their receptors to expose a new NH2-terminus. Specific residues within this tethered ligand domain interact with extracellular domains of the cleaved receptor, resulting in activation.
Protease-activated receptor 2 (PAR2), also known as thrombin receptor-like 1 (F2RL1), is a G-protein-coupled receptor (GPCR) expressed in many cell types, such as immune cells and epithelial cells of various tissues, including the gastrointestinal tract, lungs, and skin. PAR2 is activated by proteolytic cleavage of the N-terminus by extracellular serine proteases such as trypsin, tryptase, and neutrophil elastase, unmasking self-activating endogenous tether ligands. Activation of PAR2 induces multiple G-protein-mediated signaling pathways, which are involved in a wide range of physiological responses such as inflammation, cell proliferation, and angiogenesis.
The most common activation mechanism for PAR2 involves proteolysis at the "canonical" R36↓S37 site by trypsin and tryptase. Activation of PAR2 triggers intracellular calcium increase through phospholipase C/Ca²⁺/protein kinase C signaling, along with the activation of NF-κB signaling pathways. Downstream of these signaling pathways, leading to the production of inflammatory cytokines, initiates the PAR2-mediated inflammatory axis.
The intricate role of protease-activated receptor 2 (PAR2) activation, catalyzed primarily by trypsin, has captivated researchers due to its profound impact on biomedical responses and its implications in various diseases and conditions, particularly inflammation and regeneration processes. As a membrane-bound receptor involved in crucial cellular signaling pathways, PAR2 has emerged as an enticing target for therapeutic intervention, igniting substantial interest within the scientific community.
Trypsin is known to exhibit antioxidative effects, and it can influence the activation of protease-activated receptor 2. When combined with chymotrypsin, the preparation exerts additional anti-inflammatory effects: one mechanism contributing to improved healing with the trypsin:chymotrypsin combination is that it helps in maintaining high levels of α1-antitrypsin for a long duration. Consequently, the activity of proteolytic enzymes and their degradative effects are countered, leading to reduction in inflammatory milieu, reactive oxygen species (ROS) and oxidative stress, and faster healing. Additionally, the enzyme preparation also increases enzymatic and non-enzymatic antioxidant levels, which further augments its antioxidant and anti-inflammatory efficacy.
The anti-infective property of the enzyme complex may be explained by enhanced phagocytic activity of natural killer cells and macrophages due to trypsin.
The breakdown of dietary protein starts in the acidic environment of the stomach. In the small intestines, the proteolytic enzymes finish the digestion by breaking the protein down into amino acids that the body can absorb. Malabsorption can result from conditions like cystic fibrosis and chronic pancreatitis.
Clinical evidence is strongest in this domain. Pancreatic insufficiency is treated with PERT capsules which contain pancreatic extract (lipase, protease, and amylase) to replace the missing endogenous pancreatic enzymes. All current FDA-approved products are derived from porcine origin. While pancreatic enzyme replacement therapy does not completely normalize pancreatic insufficiency, it does result in an increase in fat absorption above 85% in most patients with CF, and the advent of this therapy has contributed to a significant improvement in the outcomes of these patients. Additionally, PERT allows patients with CF to eat a normal diet high in fat, absorb necessary nutrients, avoid many of the disabling GI symptoms associated with pancreatic insufficiency, and grow and develop more appropriately.
Pancreatic insufficiency is associated with cystic fibrosis in up to 85–90% of patients. Pancreatic Enzyme Replacement Therapy (PERT) is the indicated treatment to compensate for maldigestion and malabsorption of nutrients, and aims at maintaining or achieving an adequate nutritional status. The evidence base for PERT in pancreatic exocrine insufficiency is well-established and underpins multiple FDA-approved pharmaceutical products.
Evidence level: moderate, primarily from controlled trials, some with methodological limitations.
Trypsin:chymotrypsin is an oral proteolytic enzyme preparation which has been in clinical use since the 1960s. It provides better resolution of inflammatory symptoms and promotes speedier recovery of acute tissue injury than several of the other existing enzyme preparations.
A phase-IV, open-label, prospective, multi-center clinical trial examined wound healing outcomes in a post-surgical context. This study was designed to assess the safety and effectiveness of treatment with Tibrolin® (a fixed-dose combination of trypsin 48 mg, bromelain 90 mg, and rutoside 100 mg tablet) in improving wound healing and alleviating acute pain in patients following uncontaminated surgeries. A phase-IV, open-label, prospective, multi-center clinical study was conducted on 200 patients after elective, clean, uncontaminated surgery. Patients were randomized (1:1) to receive either Tibrolin® or Chymoral Forte® (trypsin-chymotrypsin) tablets, administered as two tablets to be taken orally thrice a day for seven days postoperatively. Tibrolin® was well-tolerated in the study, with no observed adverse or treatment-related adverse events. At the end of the treatment regimen, all wound healing parameters, including erythema, edema, discharge, induration, local irritation, and tenderness, showed a highly significant improvement (p < 0.001) in both treatment groups. Additionally, there was more than an 85% reduction in NPRS scores reported in both groups.
Dhadiwal et al. demonstrated that the oral administration of a trypsin-bromelain-rutoside combination resulted in about a 58% reduction in pain and swelling associated with diverse orthopedic conditions, with a statistically significant reduction in pain (p < 0.001).
Researchers have explored the use of trypsin in wound care. Some studies show that trypsin helps break down dead tissue proteins and helps with the debridement process. Trypsin supplements, both oral and topical, may help speed wound recovery. Part of wound care is debridement, which involves helping the body remove dead tissue while the new tissue forms underneath.
Evidence level: moderate, with several RCTs, though many involve combination formulas and most studies are small to medium in size.
A prospective, randomized, double-blind, placebo-controlled exploratory trial evaluated the effects of pre- and post-operative use of an oral enzyme combination (OEC: 90 mg bromelain, 48 mg trypsin, 100 mg rutoside) following elective total hip replacement (THR), on post-operative recovery. Candidates for primary elective cementless THR owing to osteoarthritis were eligible (age ≥50 years, BMI 25–35 kg/m², CRP ≤6 mg/L). Following randomization to OEC or placebo, intervention started pre-operatively and continued until day 42.
A 2017 randomized clinical trial investigated the enzyme combination in temporomandibular joint osteoarthritis. Thirty patients with symptomatic TMJ osteoarthritis were randomly divided into three groups: 10 treated with diclofenac sodium (Group 1), 10 given oral enzymes (bromelain, trypsin, rutoside trihydrate) and diclofenac sodium combination (Group 2), and 10 treated with oral enzyme preparation alone (Group 3).
A 2024 systematic review published in PMC examined these data more broadly. Very few randomized controlled trials are done on systemic enzyme therapy and its effect on TMJ disorders. Although similar studies exist with treatment for knee arthritis and wound healing, a moderate amount of bias concerning blinding and randomization exists. As the pain score is subjective, it is difficult to generalize the results. However, the analyzed studies showed improvement and were statistically significant concerning the study population. The efficiency of trypsin, bromelain, and rutoside was assessed as superior to conventional NSAIDs.
Clinical trials demonstrate the effectiveness and safety of the bromelain, trypsin, and rutoside fixed-dose combination in treating edema and inflammation and facilitating the healing of wounds. The Cochrane Library records multiple indexed trials of trypsin-containing enzyme combinations for osteoarthritis of the knee, including a 2004 double-blind prospective randomized study comparing oral enzyme combination versus diclofenac in knee osteoarthritis (Akhtar et al., indexed as CN-01298336). A 2025 proof-of-mechanism randomised, crossover, double-blind, placebo-controlled trial (Henrotin et al., RMD open, 2025) assessed whether oral enzyme combination therapy reduces systemic inflammation, urinary CTXII, and pain in knee osteoarthritis. These data are encouraging but the overall body of evidence is limited by small sample sizes and, in many studies, pharmaceutical sponsorship.
A study showed that a supplement containing bromelain and trypsin was as effective as traditional anti-inflammatory drugs at reducing osteoarthritis-related pain. Some studies suggest potential benefits for sports injuries and inflammation, but results have varied widely, with many studies lacking robust design or placebo controls.
A randomized controlled trial published by Hashem et al. (2023, Journal of Endodontics) assessed the effect of trypsin-chymotrypsin on postoperative pain after single-visit endodontic treatment. This randomized controlled trial enrolled patients to assess trypsin-chymotrypsin versus control for postoperative pain after single visit endodontic treatment.
Evidence level: preclinical (in vitro and animal models); no established clinical therapeutic use in oncology.
Extracellular proteases originally considered favorable to malignancy have a much more complex role than previously assumed, with some enzymes acting in an opposing fashion to block cancer growth and maintain tissue homeostasis. Research has revealed a paradoxical dual role for trypsin in cancer:
PAR2 has been implicated in various physiological and pathophysiological processes, including inflammatory responses, pain sensation, cellular permeability, contractility, and cancer development. Given its diverse roles, PAR2 is considered an attractive target for therapeutic interventions in conditions such as rheumatoid arthritis, asthma, chronic pain, inflammatory bowel diseases, and neurological disorders. However, all current findings in oncology are based on in vitro cell-line studies and animal models. No clinical trials have established a therapeutic role for trypsin in treating human cancer, and this area remains early-stage investigational science.
Uncontrolled trypsin enzyme activity inside the pancreas can damage tissue and contribute to pancreatitis. Trypsin reduces pancreatic ductal bicarbonate secretion via PAR-2–dependent inhibition of the apical anion exchanger and the CFTR Cl– channel. This could contribute to the development of chronic pancreatitis by decreasing luminal pH and promoting premature activation of trypsinogen in the pancreatic ducts. Trypsin is thus associated with pancreatitis in a pathological, rather than therapeutic, context.
The amount of an enzyme is expressed not only in grams or milligrams but also in activity units or international units. These terms refer to the enzyme's potency—specifically, its digestive power. Recommended dosages of proteolytic enzymes vary with the form used. Because of the wide variation, label instructions regarding dosage should be followed.
Based on the origin of the food enzyme from an edible tissue of pigs, the data provided by the applicant, the information from the evaluation of clinical studies based on pancreatic enzymes, and the estimated dietary exposure, the EFSA Panel concluded that trypsin from porcine pancreas does not give rise to safety concerns under the intended conditions of use.
In the 200-patient randomized clinical trial examining post-surgical use, Tibrolin® was well-tolerated in the study, with no observed adverse or treatment-related adverse events.
Hypersensitivity to the pharmaceuticals was identified as the major side effect. However, allergic reactions to porcine pancreatic enzymes in hydrolysed foods have not been reported. The Panel considered that a risk of allergic sensitisation to this food enzyme after consumption of products prepared by hydrolysis of milk proteins could not be excluded in infants, but it considered the likelihood to be low.
Immediate hypersensitivity to hog trypsin resulting from industrial exposure has been documented in the medical literature (Colten HR et al., New England Journal of Medicine, 1975, 292:1050–1053). Occupational exposure presenting a higher sensitization risk than dietary or oral pharmaceutical use is noted in the literature.
Patients were excluded from the trypsin/bromelain/rutoside surgical trial if they had a history of hypersensitivity to any of the ingredients of the formulation, hepatocellular insufficiency, hepatic failure, or active liver disease, severe renal impairment, a hereditary coagulation disorder, or were pregnant or breastfeeding.
In the toxicological evaluation of porcine trypsin as a food enzyme, clinical studies with pancreatic enzymes were considered. Mild gastrointestinal upset has been noted in clinical reports of enzyme supplementation. Signs and symptoms of pancreatic insufficiency including abdominal distention and discomfort, flatulence, and frequent bulky stools may have a negative impact on quality of life; enzyme supplementation is intended to correct these but must be titrated appropriately.
The Cystic Fibrosis Foundation received reports of 35 cases of colonic stricture between January 1990 and December 1994, which were considered to be related to high doses of PERT. Guidelines for dosing of PERT and avoidance of fibrosing colonopathy were published in 1995 based on a consensus conference organized by the CF Foundation in conjunction with the U.S. Food and Drug Administration (FDA). Recommendations included target doses of PERT in infants, children, and adolescents, and a warning to use caution when PERT doses exceeded 2,500 lipase units/kg/meal. This complication is associated specifically with very high doses in the context of pancreatic insufficiency treatment, not with the lower doses used in over-the-counter enzyme supplements.
Research has demonstrated that trypsin increased intracellular Ca²⁺ concentration and intracellular pH and inhibited secretion of bicarbonate by the luminal anion exchanger and the cystic fibrosis transmembrane conductance regulator (CFTR) Cl– channel. Autoactivation of human cationic trypsinogen accelerated when the pH was reduced from 8.5 to 6.0. This highlights that endogenous trypsin dysregulation — not supplemental trypsin per se — is the relevant mechanism in pancreatitis pathogenesis.
Research over the past two decades has revealed the critical roles of PAR2 in various inflammatory diseases such as arthritis, atopic dermatitis, asthma, colitis, and inflammatory bowel disease. Because trypsin is a primary activator of PAR2, there is ongoing scientific scrutiny regarding whether exogenous trypsin supplementation could activate or modulate PAR2 signaling in a clinically meaningful way in individuals with chronic inflammatory conditions. This question remains under investigation and no firm safety conclusions for these populations have been established in the clinical literature reviewed.
Very few randomized controlled trials are done on systemic enzyme therapy and its effect on inflammatory disorders. Although similar studies exist with treatment for knee arthritis and wound healing, a moderate amount of bias concerning blinding and randomization exists. As the pain score is subjective, it is difficult to generalize the results. The majority of trypsin supplement trials use combination formulas (most commonly with chymotrypsin, bromelain, and rutoside), making it impossible to attribute specific effects solely to trypsin. Many trials originate from a limited number of research centers, predominantly in India and Europe, and pharmaceutical sponsorship is common.
Health conditions that Trypsin may help support.
Multiple randomized controlled trials and a systematic review support oral enzyme combinations containing trypsin as comparable to diclofenac (NSAID) for pain and function in knee osteoarthritis. A 2025 crossover RCT also demonstrated reductions in systemic inflammation and cartilage turnover markers. Evidence is for combination products (trypsin + bromelain + rutoside).
Multiple clinical trials have evaluated oral trypsin:chymotrypsin combinations in burn patients, finding reductions in oxidative damage, modulation of cytokine levels, and acute-phase protein responses. The combination has been in clinical use for burn management since the 1960s. Evidence supports anti-inflammatory and tissue-protective roles in burn wound healing.
Trypsin and its combination preparations have demonstrated anti-inflammatory effects through multiple mechanisms including modulation of protease-inhibitor balance, fibrinolysis, and cytokine regulation. Clinical evidence supports reduction of inflammatory biomarkers following oral enzyme therapy. Memorial Sloan Kettering notes observational support but acknowledges clinical data remain limited for purely chronic conditions.
Oral trypsin-containing enzyme combinations have demonstrated analgesic effects in clinical trials across multiple pain conditions including osteoarthritis and post-surgical pain. Equivalence to NSAIDs in knee OA pain trials is the strongest evidence. Trypsin:chymotrypsin also shows analgesic properties in maxillofacial and orthopedic surgical recovery.
Trypsin is a key pancreatic serine protease that hydrolyzes proteins at lysine and arginine residues and is central to intestinal protein digestion. It is a component of pancreatin formulations and has been studied in clinical enzyme replacement therapy. It is listed in multiple authoritative pharmacopeial monographs as a core digestive protease.
Trypsin, as part of multi-enzyme combinations, has been evaluated in randomized controlled trials for recovery from exercise-induced muscle damage (EIMD). Studies show improvements in muscle function and reductions in soreness after high-eccentric-load exercise. Evidence is for combination products rather than isolated trypsin.
Trypsin-containing systemic enzyme therapy has been shown in a double-blind RCT to significantly reduce delayed onset muscle soreness (DOMS) and fatigue in athletes following eccentric exercise. The effect is attributed to modulation of inflammatory mediators. Evidence is primarily for combination enzyme products.
Trypsin is a proteolytic enzyme used in post-surgical contexts for reducing swelling, pain, and promoting wound healing. A 2024 Phase IV multicenter RCT (n=200) showed a fixed-dose combination containing trypsin significantly improved wound healing and acute pain after clean elective surgery. It is frequently used in clinical practice in enzyme combination formulations.
Trypsin:chymotrypsin combination preparations have clinical trial evidence specifically for sciatica. The PMC review (Shah & Mital, 2018) states that efficacy in sciatica is corroborated by a substantial and largely consistent body of evidence. The mechanism involves reduction of inflammation and edema around the affected nerve root.
Clinical trials, including a 721-participant double-blind RCT, have evaluated trypsin-containing enzyme preparations for ankle sprains, with mixed results. Earlier smaller studies showed faster healing; the large trial found no significant benefit. Trypsin:chymotrypsin combinations have documented evidence for soft tissue sprains and strains.
Trypsin—both topically and orally in combination—has multiple randomized clinical trials demonstrating acceleration of wound healing and reduction of edema, pain, and inflammation in post-surgical wounds. A 2025 phase-IV multi-center RCT (200 patients) confirmed trypsin/bromelain/rutoside is as efficacious as trypsin-chymotrypsin for surgical wound symptoms. Topically, trypsin removes necrotic tissue by proteolytic debridement.
Body systems that Trypsin may help support.
Go back